Ocrelizumab in Relapsing Remitting MS
Open for Enrollment
What is the Purpose of this Study?
To assess effectiveness of Ocrelizumab IV every 6 months in patients who have suboptimal response to previous DMTs.
Who is Eligible to Participate?
Age 18 to 55, MS for less than 8 years, use of only 1 or 2 MS treatments and had a relapse or MRI activity while on treatments. Patients will also meet all inclusion criteria which will be explained in greater detail by the study coordinator.
What is involved in this Study?
Study visits, MRIs, infusions (4). This will be discussed with the study coordinator.
How long is the Study?
Approximately 96 weeks
For More Information Contact: Lynne Flynn, CCRC, study coordinator, at 602-258-2863 or email@example.com